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Key Points
• CD166 identifies human and
murine long-term repopulating
stem cells.
• CD166 is a functional marker
of stem cells and the
hematopoietic niche.
We previously showed that immature CD1661 osteoblasts (OB) promote hematopoietic
stem cell (HSC) function. Here, we demonstrate that CD166 is a functional HSC marker
that identifies both murine and human long-term repopulating cells. Both murine
LSKCD482CD1661CD1501 and LSKCD482CD1661CD1501CD91 cells, as well as human
Lin2CD341CD382CD49f1CD1661cells sustained significantly higher levelsof chimerism
in primary and secondary recipients than CD1662 cells. CD1662/2 knockout (KO) LSK
cells engrafted poorly in wild-type (WT) recipients and KO bone marrow cells failed to
radioprotect lethally irradiatedWT recipients. CD1662/2 hosts supported short-term, but
not long-term WT HSC engraftment, confirming that loss of CD166 is detrimental to the
competence of the hematopoietic niche. CD1662/2 mice were significantly more sensitive to hematopoietic stress. Marrow-homed
transplantedWThematopoieticcells lodgedcloser to the recipient endosteum thanCD1662/2cells, suggesting thatHSC-OBhomophilic
CD166 interactions are critical for HSC engraftment. STAT3 has 3 binding sites on the CD166 promoter and STAT3 inhibition reduced
CD166expression, suggesting thatbothCD166andSTAT3maybe functionally coupledand involved inHSCcompetence. Thesestudies
illustrate the significance of CD166 in the identification and engraftment of HSC and in HSC-niche interactions, and suggest that CD166
expression can be modulated to enhance HSC function. (Blood. 2014;124(4):519-529)
Introduction
How hematopoietic stem cell (HSC)–hematopoietic niche (HN) inter-
actions maintain HSC function remains unknown. Several markers on
HSC have a ligand on cells of the HN. However, these markers are
neither obligatory for HSC function nor are they universally expressed
on HSC across species, or on cells of the HN. A role for osteoblasts
(OB) in maintaining HSC is well-documented.1-3 We previously
showed thatmore immature OBwith high Runx2 expressionmaintain
hematopoietic function.4 Recently, we found that anti-activated leuko-
cyte cell adhesion molecule (or CD166) expression on OB directly
correlates with Runx2 expression and high hematopoiesis–enhancing
activity.5 CD166 expression decreased with OB maturation concom-
itant with a decline in Runx2 expression and OB-mediated ex vivo
maintenance of HSC.5
Expression of CD166 on niche cells has been reported.6
CD166, which can mediate CD166-CD166 homophilic inter-
actions, is a member of the immunoglobulin superfamily and can
also bind the only other known ligand, CD6.7 CD166 was orig-
inally used to identify a subset of human adult bone marrow (BM)
and mobilized peripheral blood (PB) CD341 cells enriched for
progenitor activity.8 However, functional studies with CD166
were not pursued. CD166 expression on Stro-11 stromal cells9
and binding of hematopoietic cells via CD166 to a yolk sac-
derived stromal cell line were also demonstrated.10 These, and our
data2,4,5,11 conﬁrmed that CD166 is expressed on hematopoietic
progenitors and on OB, suggesting the unique possibility that
these cells may interact with one another through CD166-CD166
interactions.
Recently, Jeannet et al12 reported that CD166 is differentially
regulated in adult hematopoiesis and that CD1662/2 HSC have
an engraftment defect, although young CD1662/2 mice dis-
played normal hematopoietic counts and numbers of phenotyp-
ically deﬁned HSC. However, these studies12 did not examine the
potential of CD166 to identify bona ﬁde normal murine and human
HSC, nor did they investigate the functional capacity of CD166 in
the niche.
In this report, we demonstrate that CD166 is a universal func-
tional marker of murine and human HSC and OBwithin the HN.We
also demonstrate that it is involved in modulating HSC-niche inter-
actions and HSC fate. The conserved homology betweenmurine and
human CD166 provides an excellent translational bridge between
these systems to advance future interventions for enhancing HSC
engraftment and clinical beneﬁt.
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Methods
Mice, human cord blood, and transplantation
Breeding pairs of CD1662/2mice (B6.129[FVB]-Alcamtm1Jawe/J mice; stock
No. 010635) were obtained from The Jackson Laboratories. CD1662/2,
B6.SJL-Pt-cqPep3b/BoyJ (BoyJ), C57BL/6, C57BL/6-BoyJ F1, and NOD
scid g (NSG) mice were bred and housed at Indiana University. Mice 8- to
12-weeks-old were used. Recipients other than NSG mice received 1100 cGy
(700 and 400 cGy split-dose); NSGmice received 275 cGy. All procedures were
approved by the Institutional Animal Care and Use Committee of the Indiana
University School of Medicine and followed National Institutes of Health
guidelines. Human umbilical cord blood (CB) was obtained from St. Vincent’s
Hospital (Indianapolis, IN)with Institutional ReviewBoard approval. This study
was conducted in accordance with the Declaration of Helsinki. Test cells were
injected IV in 200 mL phosphate-buffered saline and where needed, 10e5
competitor cells per recipientwere used. Inmurine andhumanstudies, chimerism
was assessedmonthly in the PB and at 4- or 6-months posttransplantation (PT) in
the BM of primary recipients, as indicated. Secondary recipients received the
equivalent of half a femur from primary recipients without competitor cells.
Homing and mobilization
Homing of transplanted cells to theBMof irradiated recipientswas performed
as previously described.13 Brieﬂy, low-density BM cells were stained with
CellTrace Violet (CTV) tracking dye (Invitrogen), washed, and injected IV
into nonirradiated recipients to avoid radiation-induced injury to the marrow
microenvironment. Recipientmicewere sacriﬁced 16 hours PT, andBMcells
were recovered and analyzed for CTV1 cells. Mobilization of hematopoietic
stem and progenitor cells (HSPC) was performed as previously described.14
Cell staining, flow cytometry, and cell sorting
Cellswashedwith stainwash (phosphate-buffered saline,1%bovine calf serum,
and 1% penicillin-streptomycin) were stained for 15 minutes on ice. Low-
densityBMcellswere stainedwithﬂuorescein isothiocyanate-conjugatedCD3,
CD4,CD45R, Ter119, andGr1; allophycocyanin-conjugated c-Kit (CD117);
phycoerythrin-Cy7-conjugated Sca-1; phycoerythrin-conjugated CD166
(clone-eBioALC48; eBiosciences, catalogNo. 12-1661-82);AF700-conjugated
CD48; and PerCpCy5.5-conjugated CD150. In some experiments, ﬂuorescein
isothiocyanate-conjugated CD48 was used to simultaneously select Lin2CD482
cells. Cell sorting was performed on a BD FACSAria and ﬂow cytometric
analysis was done on a BD LSRII.
ChIP
Chromatin immunoprecipitation (ChIP) was done using IL-7-stimulated
TAIL7 cells with immunoprecipitation of protein-bound DNA sequences
performed using antibodies for STAT3 (Cell Signaling), RNA polymerase-
II (Millipore), or an irrelevant Ab (Jagged2; SantaCruzBiotechnology). After
puriﬁcation of eluted DNA, ChIP-quantitative polymerase chain reaction was
performed using sequence-speciﬁc probes for promoter regions of CD166,
Survivin, glyceraldehyde-3-phosphate dehydrogenase, or the control
open reading frame (ORF)-free intergenic region IGX1A (SABiosciences),
in a 7900HT PCR system (Applied Biosystems).
Two-photon microscopy
Mice were injected with carboxyﬂuorescein succinimidyl ester (CFSE)-
labeled cells as described in “Methods.” At 16-hours PT, mice were
anesthetized and a jugular vein catheter was inserted to allow ﬂuorescent
tracer injections on the microscope stage. The dorsal skull surface was
exposed, placed in a custom-designed atraumatic stereotaxic device, and
submerged in microscope oil. Images were acquired with an Olympus
FV1000 confocal system custom-modiﬁed for multiphoton imaging. Images
were collected in a nondescannedmode usingOlympusXLUMPLFL203W,
NA 0.95 objective, and 830 nm excitation wavelength. Imaging was per-
formed at a scan rate of 4 ms per pixel. Sections through the depth of tissue
(Z-stacks) were collected from 6 regions of the calvarium. Z-stacks were
collected at step-size settings of 1 mm and 5123 512 pixels. Image analysis
was performed using Amira 3D Visualization and Image Analysis software,
version 4.1 (FEI, Burlington, MA).
Statistical analysis
Data are presented as mean 6 standard deviation and where applicable,
triplicate samples were measured. Two-tailed Student t tests were performed
when only 2 groups were compared. One-way factorial analyses of variances
were used for multiple group comparisons. Signiﬁcance was set at 0.05.
Results
CD166 identifies murine and human long-term BM
repopulating cells
We examined the repopulating potential of CD1661 and CD1662
subsets of putative HSC rigorously identiﬁed by Lin2Sca11c-Kit1
(LSK) and signaling lymphocyte activation molecule markers.15
As shown in Figure 1A, CD166 and CD150 fractionated LSK482
cells into 4 distinct groups (ﬂuorescence minus one [FMO] controls
are shown in supplemental Figure 1A, available on the Blood Web
site). A total of 25, 50, and 100 cells from groups 1 to 4 were
competitively transplanted. Chimerism at 4 months PT (data from
25 cells/mouse shown in Figure 1B) demonstrated that engraftment
of CD1501 cells was predominantly restricted to cells coexpressing
CD166, although some low-level engraftment was observed among
CD1662CD1501 cells (group 4). The reconstitution kinetics of cells
in groups 2, 3, and 4 were strikingly different (data from 100 cells/
mouse shown inFigure1C).CD1661CD1501 cells (group3)displayed
long-term HSC (LT-HSC) kinetics, whereas CD1661CD1502 cells
(group 2) provided declining levels of repopulating potential, re-
miniscent of short-term HSC (ST-HSC) activity. CD1662CD1501
cells (group 4) appear to be intermediate-term HSC16 or LT-HSC
with a limited, but consistent, repopulating potential. Limiting dilution
analysis (LDA) (Figure 1D) revealed that the frequency of LT-HSC
was highest among CD1661CD1501 cells (1:17). Serial transplanta-
tion inwhich primary recipients received 10 cells fromgroups 1, 2, 3, or
4 (Figure 1E-F) demonstrated that CD1661CD1501 cells (group 3)
provide approximately 20-fold higher levels of chimerism than other
groups examined. The number of repopulating units17 (RU) per 10 cells
(Figure 1G) illustrated that LDA and RU calculations generated very
similar results, and ascertained that repopulating HSC among
LSK482CD1661CD1501 cells are approximately sixfold higher
than among LSK482CD1662CD1501 cells.
Analysis of multilineage differentiation at 4-months PT sug-
gested that differentiation of CD1501 cells (regardless of CD166
expression status) is skewed toward themyeloid lineage (Figure 1H),
whereas that of CD1502 cells, especially the CD1661CD1502 cells,
is skewed toward the lymphoid lineage, as previously reported for
both subgroups.18 Skewed lineage differentiation of CD1501 and
CD1502 cells was also observed in mice receiving different size
grafts (supplemental Figure 2). Recently, Karlsson et al19 re-
ported a new phenotypic characterization of murine HSC using
the tetraspanin CD9.We examined whether CD91HSC19 express
CD166. Approximately one-third of LSKCD482CD1501 cells
expressed CD9 (Figure 1I) (FMO controls shown in supplemental
Figure 1B). Only CD1661CD91 cells sustained signiﬁcant in
vivo engraftment (Figure 1J), suggesting that CD166 expression
is obligatory for the complete identiﬁcation of functional HSC.
That CD166 marks HSC was also gleaned from coexpression of
CD166 and side population cells20 (Figure 1K).
The majority of Lin2CD341CD382 cells in human umbilical
CB expressed CD166 (Figure 2A). The repopulating potential of
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Figure 1. Characterization of the functional properties of murine HSC fractionated with CD166. (A) C57BL/6 low-density BM cells were analyzed for the expression of
lineage markers and CD48 (left dot plot). Lineage-CD482 (Lin-482) cells were analyzed for the expression of Sca-1 and cKit (middle dot plot) to identify Lin-Sca11cKit1CD482
(LSK482) cells (group 1 in middle dot plot). LSK482 cells were analyzed with CD150 and CD166 (right dot plot) to define groups 2, 3, and 4. Percentages next to each group
represent the relative size of each population within the dot plot. A total of 100, 50, and 25 cells from groups 1 through 4 were transplanted into F1 mice with 10e5 BoyJ
competitor cells (5 mice/group). (B) Chimerism 4-months PT for the 25-cells/mouse group. *P , .05 vs group 3. (C) Engraftment kinetics for groups 1, 2, 3, and 4 over 4
months measured in the PB of recipients of 100-cells/mouse group. *P , .05 vs corresponding values from LSK482CD1661CD1501 cells. These data are from 1 of 3
independent experiments with similar results. (D) LDA analysis from BM engraftment at 4-months PT in mice receiving 25, 50, and 100 cells (5 mice/group). P 5 .01 for the
overall test for differences in HSC frequencies between any of the groups. Table shows the estimated frequencies and range of repopulating cells within each group tested. (E)
Chimerism at 4-months PT in primary recipients after the competitive transplantation of 10 cells/mouse from groups 1 to 4 identified in (A), along with 10e5 BoyJ competitor
cells. (F) Chimerism at 4-months PT in secondary recipients of the equivalent of one half femur from primary recipients (BM cells were collected 4-months postprimary
transplant) shown in (E) without competitor cells [4-5 mice/group in (E) and (F)]. (G) RU per 10 cells calculated from data shown in (E) as described in Harrison and Astle.17
*P , .05 vs group 3. (H) Multilineage differentiation 4-months PT of groups 1 through 4 in mice receiving 100 cells/animal. *P , .05 between LSK482CD1661CD1501 cells
and LSK482, CD1661CD1502, and CD1662CD1501 cells within each group. (I) Expression of CD166 on LSK482CD1501CD91 cells (in the 3 dot plots from L to R). (J)
Chimerism at 4-months PT in mice receiving 10 cells per mouse from groups I, II, and III transplanted competitively into F1 mice with 10e5 BoyJ competitor cells
(5 mice/group). *P , .05 vs group III. (K) Expression of CD166 on the low (L), medium (M), and high (H) fractions of murine BM side population (SP) cells. Data shown in (K)
are from 1 representative experiment from 4 independent analyses with similar results.
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Lin2CD341CD382CD1661 cells in NSG mice (Figure 2B) was
.4-fold higher than that of equal numbers of Lin2CD341CD382
CD1662 cells and far exceeded chimerism sustained by Lin2
CD341CD382 cells. Recently, CD49f (alongwith lineagemarkers,
CD34, CD38, and CD90) was used to identify robust human HSC
capable of engrafting in a xenotransplantation model at the single cell
level.21 Amodiﬁed staining protocol (Figure 2C; FMO controls shown
in supplemental Figure 1C) demonstrated that CD166 and CD49f
fractionate CB Lin2CD341CD382 cells into 4 distinct subgroups
(Figure 2C). Repopulating cells in NSG mice were predominantly
CD1661 (Figure 2D; groups 2 and 3), regardless of the status of
CD49f, suggesting that CD1661, but not CD1662 cells within the
CD341Lin2CD382 fraction contains the majority of long-term
engrafting cells. Long-term engraftment of CD49f1 cells was
principally restricted to cells coexpressing CD166, demonstrating the
importance of CD166 in identifying human LT-HSC. Serial trans-
plantation studies (cells isolated as described in Figure 2C) conﬁrmed
that CD1661, but not CD1662 cells sustained durable long-term
engraftment (groups 2 and 3) (Figure 2E-F). CD166 identiﬁed similar
subgroups in adult human BM (supplemental Figure 3) illustrating
that CD166 identiﬁes putative HSC from different hematopoietic
tissues at different stages of ontogeny.
CD1662/2 HSC do not engraft in WT recipients
Because CD166 is expressed byHSC (Figure 1) andOB is critical for
their function,2,11 we reasoned it may play an important role in the
niche via CD166-mediated HSC–OB interactions. To investigate the
role of CD166 in hematopoiesis, we examined the functional
properties of HSC from CD166 knockout (KO) mice. As expected,
BM cells from the central region, considered here the vascular niche,
and from ﬂushed and then digested bones, considered here the en-
dosteal region of KO mice did not express CD166 (supplemental
Figure 4A) nor did OB from these mice (supplemental Figure 4B).
Absolute numbers of LSK482 and LSK482CD1501 cells in the BM
and Lin2CD482 cells in the PB of CD1662/2micewere signiﬁcantly
reduced (Figure 3A). Lineage composition in the central region
revealed that KO mouse BM contained a slightly, but signiﬁcantly,
higher percentage of lymphoid cells and a slightly, but signiﬁcantly,
lower percentage ofmyeloid cells (supplemental Figure 5A).However,
cell composition in the endosteal fraction did not show signiﬁcant
differences betweenWT andKOmice (supplemental Figure 5B). The
frequency of HSPC including LSK, LT-HSC (LSKCD342CD1352),
and CD1501LT-HSC was signiﬁcantly lower in the BM of KO mice
(Figure 3B), although the frequencies of multipotent progenitors
(MPP) (LSKCD341CD1351) and ST-HSC (LSKCD341CD1352)
were not signiﬁcantly reduced in KO mice (Figure 3B). The
clonogenic potential of steady state BM- and PB-derived progenitors
was signiﬁcantly reduced in the BM and PB of KOmice (Figure 3C).
However, CD1662/2 mice mobilized normally in response to granu-
locyte colony-stimulating factor (G-CSF), although the overall
number of circulating clonogenic progenitors was signiﬁcantly
lower than in WT mice (Figure 3D), suggesting that CD166 may
play a role in G-CSF–induced mobilization of HSPC. The size and
cellularity of the spleens of CD1662/2 mice were not different than
those of WT mice.
Figure 2. Characterization of the functional properties of human CB-derived HSC fractionated with CD166. (A) Human CB cells were analyzed with a combination of
lineage markers, CD34 and CD38 and Lin2CD341CD382 cells (group 1) were analyzed for the expression of CD166 to identify CD341CD382CD1662 (group 2) and CD341
CD382CD1661 (group 3) cells. Percentages next to each group represent the relative size of each population within the dot plot. (B) A total of 5000 cells from groups 1, 2, and
3 were transplanted into NSG mice and chimerism was assessed 4-months later (n 5 3-4 per group). *P , .05, CD341CD382CD1661 vs other groups. (C) Fractionation of
human CB cells with CD34 and a combination of lineage markers and CD38 to select Lin2CD341CD382 cells (group 1 in left dot plot). Lin2CD341CD382 cells were analyzed
with CD166 and CD49f (right dot plot) to define groups 2, 3, 4, and 5. Percentages next to each group represent the relative size of each population within the dot plot. A total
of 1000 cells from groups 1 through 5 were transplanted into NSG mice. (D) BM chimerism 4-months PT |(n 5 3-4 per group). *P , .05, groups 2 and 3 vs other groups.
Similar results were obtained in another independent experiment (4000 cells/group; n 5 4/group). The 2 data sets were not pooled. (E-F) Chimerism at 4-months PT (E)
sustained by 1000 cells per mouse from groups 1 to 4, as shown in panel (C) and in secondary recipients (F) transplanted with BM cells collected from primary recipients
(one-half a femur equivalent from pooled BM cells per recipient) shown in (E) (n5 4-5 per group in [E] and [F]). *P , .05, groups 2 and 3 vs other groups. (F) Flow cytometric
analysis of representative mice from (F) are shown in supplemental Figure 10.
522 CHITTETI et al BLOOD, 24 JULY 2014 x VOLUME 124, NUMBER 4
For personal use only.on December 23, 2016. by guest  www.bloodjournal.orgFrom 
Figure 3. Hematopoietic parameters of CD1662/2mice. (A) Absolute numbers of LSK482 and LSK4821501 cells in the BM and Lin-482 cells in the PB of WT and KO mice
(6 mice per group). *P , .05 compared with WT. (B) Percentages of HSPC classes in the marrow of WT and KO mice (6 mice/group). Classes of HSPC were identified
as such: LSK (Lin2Sca11Kit1); MPP (LSKCD341CD1351); ST-HSC (LSKCD341CD1352); LT-HSC (LSKCD342CD1352); 1501LT (CD1501LSKCD342CD1352). *P , .05
compared with WT. (C) Numbers of colony forming unit-granulocyte/macrophage (CFU-GM) in 1 mL of PB and in BM contained in 1 femur from WT and KO mice (n 5 5-6
mice per group). *P , .05 compared with WT. (D) Numbers of CFU-GM in 1 mL of PB and in BM contained in 1 femur from WT and KO mice mobilized with G-CSF (2 daily
injections of 1 mg/mouse for 4 days). Cells were collected on day 5 (n5 4-5 mice per group). *P, .05 between KO and WT vehicle (Veh) control. #P, .05 compared with Veh
in each set. †P , .05 between G-CSF KO and WT. Values in parentheses are fold-increase in CFU-GM numbers between Veh and G-CSF in each tissue. (E) Lethally
irradiated F1 mice (n 5 13 per group from 3 independent experiments) received 1000 LSK cells from the central region of CD1662/2 mice plus 10e5 CD45.1 competitor cells.
*P , .05 compared with WT at corresponding time point. (F) BM chimerism at 4-months PT of LSK cells from 1 of the 3 experiments in (E). *P , .05 compared with WT. (G)
Lethally irradiated F1 mice (n 5 5 per group) received 1000 LSK cells from the endosteal region of CD1662/2 mice plus 10e5 CD45.1 competitor cells. *P , .05 compared with
WT at corresponding time point. (H) Engraftment of 1000 GFP1 LSK cells from GFP1WT mice transplanted with 10e5 CD45.1 competitor cells into lethally irradiated WT or KO
mice (n 5 5 per group). *P , .05 compared with WT at corresponding data points. Chimerism is reported as a percentage of GFP1 cells in PB. (I) BM chimerism at 4-months
PT of GFP1 LSK cells in mice in (H). *P , .05 compared with WT. (J) Survival of lethally irradiated recipients (700 and 400 cGy split dose) over a 30-day period after
transplantation with 10e5 low-density BM cells fromWT or KO donors. *P, .05 compared with WT group. (K) Numbers of colony-forming units per 10e3 sorted LSK cells from
the BM of WT or KO donors retained on WT or KO OB after 16 hours of coculture of both cell types. *P , .05 compared with WT OB-LSK coculture. (L) Fold increase in the
number of colony-forming unit produced after 7 days of coculture combinations as shown in the table. Each culture received 1000 LSK cells on day 0. Data are reported as
fold-increase relative to the colony-forming unit number obtained from freshly isolated 1000 LSK cells on day 0. *P , .05 compared with WT OB and CD1661 LSK coculture
(third bar from the left). (M) Expression of different adhesion markers on BM cells from WT and CD1662/2 donors. All antibodies were obtained from Becton-Dickinson or
Pharmingen.
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LSK cells from KO mice collected from the central (Figure 3E-F)
or endosteal regions (Figure 3G) almost failed to engraft in lethally
irradiated recipients. Given the low chimerism levels in primary
recipients, secondary transplants were not performed.Multilineage
differentiation analysis demonstrated a signiﬁcant increase in lym-
phoid and a signiﬁcant decrease inmyeloid reconstitution in recipients
of KO cells (supplemental Figure 6) reﬂecting the same skewness in
KO mice (supplemental Figure 5). When used as recipients of LSK
cells from GFP C57BL/6 mice, only short-term repopulating cells
engrafted efﬁciently in KO mice (Figure 3H). Chimerism in WT
recipients at 4-months PT was more than 12-fold higher than in KO
hosts (Figure 3I), demonstrating that the CD1662/2 HN cannot
support LT-HSC engraftment. In addition, BM cells from KOmice
also had a compromised radioprotective function (Figure 3J).
Homophilic interactions between CD166 expressed on OB and
LSK cells was evident from adherence studies in which signiﬁcantly
fewer KO clonogenic cells within the LSK fraction adhered to OB
when either, or both LSK and OB, were derived from KO mice
(Figure 3K). The negative impact of the loss of homophilic CD166
interaction between OB and LSK was evident in the number of
clonogenic cells produced in mixed cocultures (Figure 3L). The
highest level of loss of hematopoietic function was evident between
cocultures of WT OB plus CD1661 LSK cells and KO OB plus
CD1662 LSK cells (bars 3 and 6 in Figure 3L). These data demon-
strate that selection of CD1661 LSK cells enriches hematopoietic
progenitor cell activity and suggests that other HSC-OB compen-
satory adhesion interactions may be operable. However, we did not
detect any signiﬁcant difference in the expression patterns of several
adhesion molecules on WT or KO marrow cells (Figure 3M).
Stress response and homing of hematopoietic cells from CD166
KO mice
The behavior of CD1662/2 LSK cells and the compromised
competence of the HN of KO mice prompted us to examine the
response of KO HSPC to stress. Following a single 150 mg/kg BW
injection of 5-ﬂuorouracil (5-FU), survival of CD1662/2 mice was
signiﬁcantly reduced compared withWTmice (Figure 4A). The BM
cellularity of surviving KO mice 5, 10, 17, and 24 days after 5-FU
injection was unchanged from that ofWTmice (Figure 4B). At these
time points, some classes of HSPC,22,23 speciﬁcally LSK, LT-HSC
(LSKCD342CD1352), and granulocyte-macrophage progenitors
(Lin2Sca12CD1171CD341CD16/32w1), were signiﬁcantly reduced
inKO relative toWTmice (Figure 4C), whereas recovery of ST-HSC,
MPP, common lymphoid progenitor, common myeloid progenitor,
andmegakaryocyte-erythroid progenitor was not different between the
2 genotypes (Figure 4C). A signiﬁcantly larger fraction of day 0, day 5,
day 10, day 17, and day 24 KO LSK cells were in G1 and S/G21M
phases of the cell cycle (Figure 4D-E), demonstrating the cell cycle-
dependent sensitivity of KO HSPC to 5-FU.
We also assessed CD166 expression on LSK cells in response to
radiation. BM cells from irradiated mice exhibit a persistent engraft-
ment defect postirradiation,24,25 whereas those from mice treated
with 5-FU engraft successfully.26 Expression of CD166 on LSK from
sublethally irradiated mice was signiﬁcantly reduced (Figure 4F).
However, 5-FU treatment did not signiﬁcantly reduce CD166 expres-
sion, suggesting that the engraftment defect observed in cells exposed
to radiation may be associated with decreased CD166 expression.
Homing of KO cells to the endosteal or central regions of the
marrow of KO recipients was inefﬁcient (Figure 5A). Using intravital
imaging, we examined the behavior of BM-homed transplanted cells
to assess the impact of CD166 on interactions between transplanted
cells and elements of the HN. Figure 5B illustrates that both WT and
KO cells home to the marrow of both genotypes. However, distances
betweenWT cells and the endosteumofWT recipients (supplemental
Figure 7) were signiﬁcantly shorter than those measured between KO
cells homed to the marrow of KO mice and the endosteum of these
recipients (Figure 5C). Interestingly, this defect was not as pro-
nounced (Figure 5C) when CD166 was absent on either transplanted
cells or the endosteumof recipientmice only (KO→WTorWT→KO),
suggesting that other compensatory adhesion interactions between
transplanted HSC and the endosteum are also critical for HSC func-
tion. Most importantly, differences in the settings WT→WT vs
KO→KO were consistent whether grafts contained low-density BM
cells (data not shown), lineage depleted BM cells, or LSK cells
(Figure 5C). A smaller percentage of BM-homed KO cells from the
central regionwere inG0/G1comparedwithWTcells (Figure 5D), but
these differences were not signiﬁcant, which suggests that increased
cell cycle kinetics27,28 are most likely not responsible for the gradual
decline in the engraftment of these cells. Interestingly, expression of
CXCR4 on KO HSPC cells was not altered (Figure 5E), suggesting
that CD166 is not involved in directed homing of HSPC to the BM.
Bone phenotype and function in CD166 KO mice
Toassess the impact of loss ofCD166onOBphenotype and function,
we analyzedmultiple properties ofOB fromKOmice. A signiﬁcantly
smaller fraction of 2-day calvarial OB from KOmice were in G0/G1
during days 1 and 2 of culture (supplemental Figure 8A). Except for
alkaline phosphatase, expression of messenger RNA levels of
collagen type 1, osteocalcin, osteopontin, and Runx2, were similar
between WT and KO OB (supplemental Figure 8B). Expression of
HoxB4 andN-cadherin, which have been implicated inmaintaining
HSC function,29-31 but not stromal cell-derived factor 1 were sig-
niﬁcantly lower among KO OB (supplemental Figure 8C). Al-
though these changes were signiﬁcant, they were not substantial
suggesting that reduced signaling through HoxB4 and N-cadherin
may play a role in the altered function of HSPC from KO mice and
the diminished competence of the CD1662/2 HN. Expression
levels of ﬁbulins, which negatively inﬂuence the adhesive properties
of the endosteal niche,32 were signiﬁcantly increased in KO OB
(supplemental Figure 8D), suggesting that loss of CD166 upregu-
lates the expression of ﬁbulins and indirectly reduces the adhesive
properties of OB, possibly through increased expression ofMMP2,
a pathway known to be triggered by CD166.33
CD166 regulation
We analyzed the promoter region of CD166 and recognized the
presence of 3 consensus motifs for STAT3 binding. Interestingly,
using a hematopoietic cell-targeted deletion of STAT3,34we recently
established that the engraftment potential of STAT32/2 BM cells
was signiﬁcantly reduced.35 Chromatin immunoprecipitation with
polymerase-II using the leukemia cell line TAIL7,36 which exhibits
STAT3 activation and strong expression of CD166 (supplemental
Figure 9), showed signiﬁcant enrichment in GAPDH, but not of the
control ORF-free intergenic region IGX1A (Figure 6A). However,
immunoprecipitation with STAT3 antibody showed marked enrich-
ment for the CD166 promoter sequence, as well as for Survivin,
awell-known transcriptional target of STAT3. To determinewhether
STAT3 transcriptional activity regulates CD166 expression onHSC,
we examined BM cells from WT and STAT32/2 mice. Figure 6B
illustrates a substantial decrease in the percentage of CD1661 cells
within the LSK and LSK482CD1501 fractions in STAT32/2 mice
relative to controls. Expression of CD166 was signiﬁcantly reduced
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Figure 4. Behavior of CD1662/2 HSPC under hematopoietic stress. (A) Survival of WT and KO mice after a single intraperitoneal injection of 5-FU (150 mg/kg, arrowhead)
(n5 14 per genotype). Survival was monitored daily. *P, .05; Kaplan-Meyer curves were analyzed with a log-rank (Mantel-Cox) nonparametric test. (B) Total white blood cell
count per femur before (day 0) and on days 5, 10, 17, and 24 after treatment with 5-FU (n 5 4 per genotype per time point). *P , .05 compared with WT. (C) Phenotypic
analysis of HSPC from BM of WT and KO mice 5, 10, 17, and 24 days post 5-FU (n5 4 per genotype per time point). *P, .05 compared with WT. (D) Representative analysis
of LSK cells from 1 mouse per genotype per time point with Hoechst 33342 and Pyronin Y (n 5 4 per genotype per time point). (E) Percentage of LSK cells in the G0 phase of
cell cycle on days 5, 10, 17, and 24 post-5-FU treatment analyzed as shown in (D) (n 5 4 per genotype per time point). *P , .05 compared with WT. (F) Expression of CD166
on BM-derived LSK cells from 1 representative control mouse or from each of 3 separate mice irradiated with 400 cGy or treated with 150 mg/kg 5-FU 10 days earlier.
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on murine BM-derived Lin2 cells treated for 24 hours with the
STAT3-selective inhibitor STATTIC (Figure 6C). Finally, suppres-
sion of STAT3 expression with short hairpin RNA concomitantly
reduced CD166 expression on MOLT4 cells (Figure 6D). Collec-
tively, these data suggest that expression ofCD166 can bemodulated
by STAT3 and present the possibility that loss of engraftment
potential of STAT32/2 cells35 is most likely linked to decreased
CD166 expression on these cells.
Discussion
Interactions between HSC and cells of the HN, which are vital for
stem cell pool maintenance, depend on ligand-receptor molecules
coexpressed independently on interacting cells. Among the most
characterized interactions in the HN are those between HSC andOB,
which sustain HSC functions, especially self-renewal.1,3,6 To date,
not a single, functional surface marker has been identiﬁed as a
common marker on murine and human HSC and on cells of the HN,
nor has there been any description of amarker capable of homophilic
interactions that is coexpressed on all these cell types.
Using strict phenotypic deﬁnitions of murine15 and human21
engrafting cells, we demonstrated that CD166 is a critical and
functional common marker that positively identiﬁes repopulating
HSCbeyondwhat is currently possiblewith previous approaches. To
our knowledge, this is the ﬁrst report to describe a common func-
tional marker on both human and murine HSC, and to demonstrate
that loss of this marker not only impacts stem cell function, but also
compromises the competence of the HN. In addition, we also dem-
onstrate a possible novel regulatory pathway impacting HSC
function that involves STAT3-mediated regulation of CD166 ex-
pression. STAT3, which plays a signiﬁcant role in the hematopoietic
system, is activated by several factors involved in homeostatic and
stress hematopoiesis, including IL-6, G-CSF, erythropoietin, throm-
bopoietin, and leukemia inhibitory factor. Although STAT3 deletion
markedly decreases the hematopoietic repopulating ability,35 little is
known about the downstream effectors of this defect. Our studies
demonstrate a direct link between loss of STAT3 in HSC and
decreased CD166 expression (Figure 6B) and we suggest this
pathway as a possible explanation for the decreased repopulating
potential of STAT32/2BMcells and a likely tentativemechanism for
the role of STAT3 in hematopoiesis.
In our transplantation studies, the signiﬁcant majority of both
murine and human long-term repopulating cells were CD1661,
demonstrating the importance of CD166 in identifying LT-HSC in
both species. The degree to which CD166 facilitated the enrichment
of long-term repopulating cells was evident from the frequency of
these cells among LSK482CD1661CD1501 cells (1:17). Although
Figure 5. Homing of CD1662/2 cells to the hemato-
poietic niche. (A) Homing of CD1662/2 hematopoietic
cells to the BM of lethally irradiated recipients. Recovery
of BM-homed cells 16-hours PT (corrected for total body
BM). Cells were stained with CTV, injected into lethally
irradiated recipients and then recovered from flushed
central (C BM) or from digested endosteal (E BM)
regions (n 5 3-4 mice per group). *P , .05 compared
with WT. (B) Intravital images of CFSE-stained Lin2
cells in the calvariae of nonirradiated recipients 16-
hours PT. Panels on the left depict WT cells in WT
recipients and those on the right show KO cells in KO
recipients. Top 2 panels show CFSE-stained cells
(green) in the BM microenvironment. Images of vessels
(collected at 605 nm) that were stained with tetramethyl
rhodamine isothiocyanate (TRITC)–conjugated dextran
appear in red. Images in themiddle row depict 2 different
areas of the calvarium with the bone rendered silver to
facilitate visualization of marrow-homed cells. The
bottom row shows the same areas depicted in the
middle row after removal of the images of the vascula-
ture. Distances from each cell to the surface of the
endosteumwas measured using Amira 3D Visualization
and Image Analysis software, version 4.1, using a 3-
dimensional caliper tool. Additional information can be
found in supplemental Figure 7. (C) Average distances
between WT or KO Lin2 and LSK cells and the
endosteum. Distances between cells and the bone
surface (reconstructed with a constant threshold value,
visible in gold) were measured using a 3-dimensional
caliper tool. *P, .05 comparedwithWT.Data shownare
from 1 representative experiment from a total of 3. At
least 1 recipient mouse per condition was used in
each experiment. In the analysis shown between 8 and
25 cells per condition were measured for the Lin2 group
and 5 to 7 for the LSK group. Similar data were obtained
in the other experiments. (D) Cell cycle analysis of BM-
homed cells for 16-hours PT. BM homed CTV1 cells
were isolated by cell sorting, stained with propidium
iodide, and flow cytometrically analyzed for cell cycle
status to determine cells in G0, G1, and G21M (n5 3-4
per group). (E) Frequencies of WT and KO marrow-
derived LSK and LSK48-1501 cells expressing CXCR4
(BD, clone 2B11, cat# 561734).
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the frequency of 1:17 LT- HSC among this phenotype is lower than
the 1:3 frequency reported by Kiel et al15 for CD1501 cells,
calculation of the frequency of RUs using a different approach17
yielded results (,2 RU per 10 cells, Figure 1G) almost identical to
those from Kiel et al.15 These analyses suggest that exact HSC
enumeration or quantiﬁcation may be limited by the sensitivity of
the currently available experimental protocols and subtle differ-
ences betweenpractices in different laboratories. Similar observations
can be made regarding CD49f in the human system. Although our
studies do not contradict the ﬁndings of Notta et al,21 they suggest
that only a subfraction of CD49f1 cells that also expresses CD166
contains bona ﬁde marrow reconstituting cells.
Our current and previous investigations2,4,5,11 illustrate that
CD166 is a functional marker on both HSC and OB. Functionality
of CD166 was demonstrated by the almost complete inability of
CD1662/2LSKcells to engraft inWT recipients and by the failure of
the CD1662/2microenvironment to support the engraftment of WT
LT-HSC. Furthermore, recent data (B.R.C. and E.F.S., unpublished
observations) suggest that human CB cells treated with CD166 short
hairpin RNA have a reduced engraftment potential in NSG mice,
suggesting again that CD166 is a functional marker of engrafting
stem cells. Imaging data suggest that simultaneous expression of
CD166 on HSC, as well as cells of the niche, is critical for en-
graftment and repopulation. Our results are consistent with those
reported by Jeannet et al,12 in which the engraftment potential of
puriﬁedCD1662/2LSKcells in secondary transplantation recipients
was signiﬁcantly reduced.
Although loss of CD166 did not repress the expression of other
stem cell markers on putative HSC, homing of CD1662/2 cells to the
marrow of CD1662/2 recipients was signiﬁcantly compromised
(Figure 5A). Jeannet et al12 only examined the homing of KO cells
to the BM of WT recipients, and hence no defect in homing was
observed. Our data (Figure 5A) demonstrate that overall, the homing
of KO cells to the BM is inefﬁcient, and that homing of KO cells to
the microenvironment of KO recipients is signiﬁcantly reduced.
In the studies of Jeannet et al,12 the HN of KO mice was not ana-
lyzed. Because CXCR4 expression on CD1662/2 HSPC is normal
(Figure 5E), it suggests that CD166 may not play a critical role in
homing and retention of HSPC in the marrow, but it may be critical
for HSC–HN interactions that ensure survival and function of these
cells. Imaging studies (Figure 5) conﬁrm this premise and lend
support to the suggestion that CD166 may be critical for HSC–OB
interactions that sustain stem cell survival and engraftment. More
deﬁnitive studies are required to ascertain the role of CD166 in HSC-
niche interactions. Our studies examined lodgment of marrow-
homedCD1662/2 cells under permutations not examined by Jeannet
et al,12 perhaps leading to different conclusions regarding homing of
KO cells to the BM of recipient mice.
The extent to which loss of CD166 impacts HSC function and the
fact that KO mice are viable with no apparent major defects is
interesting. Although the engraftment defect of CD1662/2 HSC is
severe and almost total, the defect observed in the HN of CD1662/2
mice is partial. Collectively, data (in Figure 3H,J) suggest that
ST-HSC survive momentarily in KO mice, but are quickly depleted
Figure 6. STAT3 regulation of CD166 expression. (A)
ChiP analysis of the binding of STAT3 to the CD166
promoter. Data are from 1 representative experiment
from a total of 3 that showed very similar results in each.
(B) CD166 expression on LSK and LSK4821501 cells
from WT and STAT32/2 mice (n 5 3 mice per group).
Data shown are from 1 mouse/genotype. Identical
results were obtained from the other 2 mice. LSK cells
were gated from column “A” and LSK4821501 were
gated from column “B.” (C) CD166 expression on BM-
derived Lin2 cells treated with STATTIC for 24 hours.
Percentage of CD1661 cells declined from 53% (solid
line plot) to 17% (dotted line plot) after treatment. (D)
Expression of CD166 in humanMOLT4 cells transduced
with scrambled (Src), CD166, or STAT3 short hairpin
RNA. Short hairpin RNA was cloned into Age1 and
EcoR1 sites of the MISSION vector (Sigma), which was
then selected by puromycin.
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early after transplantation. These defects predict an acute hemato-
poietic injury in CD1662/2 mice that would impact survival. The
susceptibility of CD1662/2mice to metabolic stress underscores the
abnormalities of their hematopoietic system that are not detected
under steady-state hematopoiesis. Our data suggest that loss of CD166
is more critical for HSC function than for the competence of the HN,
and highlight OB differentiation and maturation irregularities in
CD1662/2 mice that may partially contribute to the overall defect of
the HN. A more detailed analysis of the bones of KOmice (presented
elsewhere) revealed defects thatmay also partially contribute to loss of
niche competence. Nevertheless, our analysis documents signiﬁcantly
higher levels of alkaline phosphatase messenger RNA in CD1662/2
OB (supplemental Figure 8B), suggesting that these OB are more
mature than their WT counterparts. Because we have already demon-
strated that immature CD1661 OB are responsible for the hemato-
poiesis enhancing activity,2,4,5,11 these data suggest that maturation of
OBmay be a contributing factor to the inability of the HN of KOmice
to support the engraftment of LT-HSC (Figure 3H). Our studies also
illustrated that HoxB4 and N-cadherin expression is moderately, but
signiﬁcantly reduced in OB from KO mice. Although the importance
of HoxB4 in sustaining HSC function is well-documented,37 the role
of N-cadherin in hematopoiesis is controversial.31,38 Whether the
observed differences in the expression levels of HoxB4 andN-cadherin
contribute to the inability of the KOmicroenvironment to support
LT-HSC engraftment remains to be determined.
Acknowledgments
The authors thank the operators of the IndianaUniversityMelvin and
Bren Simon Cancer Center Flow Cytometry Resource Facility for
their outstanding technical help and support. This work was sup-
ported in part by National Heart, Lung, and Blood Institute grant
HL55716 (E.F.S.) and the Indiana Center for Excellence in Mole-
cular Hematology (National Institute of Diabetes and Digestive
and Kidney Diseases grant P30 DK090948). The FlowCytometry
Research Facility is partially funded by National Cancer Institute
grant P30 CA082709.
We acknowledge the In Vivo Therapeutics Core of the Indiana
University Simon Cancer Center (partially funded by National
Cancer Institute grant P30 CA082709 and National Institute of
Diabetes and Digestive and Kidney Diseases grant P01 DK090948)
as well as the nursing staff and Dr Arthur Baluyut at the St. Vincent
Hospital (Indianapolis, IN) for providing umbilical CB samples for
this study.
Authorship
Contribution: B.R.C. performed the majority of experimental work
and assisted in writing the paper; M.K. performed many animal
studies; Y.-H.C. performed all experimental work involving prep-
aration and culturing of OB; H.Z. performed all chromatin
immunoprecipitation studies; B.A.P. contributed to ex vivo culture
studies and animal work; H.E.B. and L.M.P. contributed to data
analysis and interpretation; H.H. contributed to experimental de-
sign and data analysis; A.Z. assisted in animal preparation for the
imaging studies and performed imaging; M.M.K. performed a
substantial volume of the imagingwork and analyzed imaging data;
N.C. and A.A.C. assisted in experimental design, data interpreta-
tion and animal modeling; M.A.K. designed all the work related to
OB preparation and culturing, helped in the design of other experi-
ments, and assisted inwriting themanuscript; and E.F.S. designed the
research, interpreted data, assisted in some experimental work, and
wrote the manuscript.
Conﬂict-of-interest disclosure: The authors declare no competing
ﬁnancial interests.
Correspondence: Edward F. Srour, Indiana University School of
Medicine, 980 W Walnut St, R3-C312, Indianapolis, IN 46202;
e-mail: esrour@iupui.edu.
References
1. Calvi LM, Adams GB, Weibrecht KW, et al.
Osteoblastic cells regulate the haematopoietic
stem cell niche. Nature. 2003;425(6960):841-846.
2. Chitteti BR, Cheng YH, Poteat B, et al. Impact of
interactions of cellular components of the bone
marrow microenvironment on hematopoietic stem
and progenitor cell function. Blood. 2010;115(16):
3239-3248.
3. Zhang J, Niu C, Ye L, et al. Identification of the
haematopoietic stem cell niche and control of the
niche size. Nature. 2003;425(6960):836-841.
4. Chitteti BR, Cheng YH, Streicher DA, et al.
Osteoblast lineage cells expressing high levels of
Runx2 enhance hematopoietic progenitor cell
proliferation and function. J Cell Biochem. 2010;
111(2):284-294.
5. Chitteti BR, Cheng YH, Kacena MA, Srour EF.
Hierarchical organization of osteoblasts reveals
the significant role of CD166 in hematopoietic
stem cell maintenance and function. Bone. 2013;
54(1):58-67.
6. Nakamura Y, Arai F, Iwasaki H, et al. Isolation
and characterization of endosteal niche cell
populations that regulate hematopoietic stem
cells. Blood. 2010;116(9):1422-1432.
7. Bowen MA, Bajorath J, D’Egidio M, et al.
Characterization of mouse ALCAM (CD166): the
CD6-binding domain is conserved in different
homologs and mediates cross-species binding.
Eur J Immunol. 1997;27(6):1469-1478.
8. Uchida N, Yang Z, Combs J, et al. The
characterization, molecular cloning, and
expression of a novel hematopoietic cell antigen
from CD341 human bone marrow cells. Blood.
1997;89(8):2706-2716.
9. Corte´s F, Deschaseaux F, Uchida N, et al. HCA,
an immunoglobulin-like adhesion molecule
present on the earliest human hematopoietic
precursor cells, is also expressed by stromal cells
in blood-forming tissues. Blood. 1999;93(3):
826-837.
10. Ohneda O, Ohneda K, Arai F, et al. ALCAM
(CD166): its role in hematopoietic and endothelial
development. Blood. 2001;98(7):2134-2142.
11. Cheng YH, Chitteti BR, Streicher DA, et al. Impact
of maturational status on the ability of osteoblasts
to enhance the hematopoietic function of stem
and progenitor cells. J Bone Miner Res. 2011;
26(5):1111-1121.
12. Jeannet R, Cai Q, Liu H, Vu H, Kuo YH. Alcam
regulates long-term hematopoietic stem cell
engraftment and self-renewal. Stem Cells. 2013;
31(3):560-571.
13. Jetmore A, Plett PA, Tong X, et al. Homing
efficiency, cell cycle kinetics, and survival of
quiescent and cycling human CD34(1) cells
transplanted into conditioned NOD/SCID
recipients. Blood. 2002;99(5):1585-1593.
14. Fukuda S, Bian H, King AG, Pelus LM.
The chemokine GRObeta mobilizes early
hematopoietic stem cells characterized by
enhanced homing and engraftment. Blood. 2007;
110(3):860-869.
15. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH,
Terhorst C, Morrison SJ. SLAM family receptors
distinguish hematopoietic stem and progenitor
cells and reveal endothelial niches for stem cells.
Cell. 2005;121(7):1109-1121.
16. Benveniste P, Frelin C, Janmohamed S, et al.
Intermediate-term hematopoietic stem cells with
extended but time-limited reconstitution potential.
Cell Stem Cell. 2010;6(1):48-58.
17. Harrison DE, Astle CM. Short- and long-term
multilineage repopulating hematopoietic stem
cells in late fetal and newborn mice: models for
human umbilical cord blood. Blood. 1997;90(1):
174-181.
18. Weksberg DC, Chambers SM, Boles NC, Goodell
MA. CD150- side population cells represent
a functionally distinct population of long-term
hematopoietic stem cells. Blood. 2008;111(4):
2444-2451.
19. Karlsson G, Ro¨rby E, Pina C, et al. The
tetraspanin CD9 affords high-purity capture of all
528 CHITTETI et al BLOOD, 24 JULY 2014 x VOLUME 124, NUMBER 4
For personal use only.on December 23, 2016. by guest  www.bloodjournal.orgFrom 
murine hematopoietic stem cells. Cell Rep. 2013;
4(4):642-648.
20. Goodell MA, Brose K, Paradis G, Conner AS,
Mulligan RC. Isolation and functional properties
of murine hematopoietic stem cells that are
replicating in vivo. J Exp Med. 1996;183(4):
1797-1806.
21. Notta F, Doulatov S, Laurenti E, Poeppl A,
Jurisica I, Dick JE. Isolation of single human
hematopoietic stem cells capable of long-term
multilineage engraftment. Science. 2011;
333(6039):218-221.
22. Bryder D, Rossi DJ, Weissman IL. Hematopoietic
stem cells: the paradigmatic tissue-specific stem
cell. Am J Pathol. 2006;169(2):338-346.
23. Kobayashi M, Srour EF. Regulation of murine
hematopoietic stem cell quiescence by Dmtf1.
Blood. 2011;118(25):6562-6571.
24. Chua HL, Plett PA, Sampson CH, et al. Long-term
hematopoietic stem cell damage in a murine
model of the hematopoietic syndrome of the acute
radiation syndrome. Health Phys. 2012;103(4):
356-366.
25. Wang Y, Schulte BA, LaRue AC, Ogawa M, Zhou
D. Total body irradiation selectively induces
murine hematopoietic stem cell senescence.
Blood. 2006;107(1):358-366.
26. Lin KK, Rossi L, Boles NC, Hall BE, George TC,
Goodell MA. CD81 is essential for the re-entry of
hematopoietic stem cells to quiescence following
stress-induced proliferation via deactivation of the
Akt pathway. PLoS Biol. 2011;9(9):e1001148.
27. Danet GH, Lee HW, Luongo JL, Simon MC,
Bonnet DA. Dissociation between stem cell
phenotype and NOD/SCID repopulating activity in
human peripheral blood CD34(1) cells after ex
vivo expansion. Exp Hematol. 2001;29(12):
1465-1473.
28. Glimm H, Oh IH, Eaves CJ. Human hematopoietic
stem cells stimulated to proliferate in vitro lose
engraftment potential during their S/G(2)/M transit
and do not reenter G(0). Blood. 2000;96(13):
4185-4193.
29. Beslu N, Krosl J, Laurin M, Mayotte N, Humphries
KR, Sauvageau G. Molecular interactions
involved in HOXB4-induced activation of HSC
self-renewal. Blood. 2004;104(8):2307-2314.
30. Haug JS, He XC, Grindley JC, et al. N-cadherin
expression level distinguishes reserved versus
primed states of hematopoietic stem cells. Cell
Stem Cell. 2008;2(4):367-379.
31. Hosokawa K, Arai F, Yoshihara H, et al.
Knockdown of N-cadherin suppresses the long-
term engraftment of hematopoietic stem cells.
Blood. 2010;116(4):554-563.
32. Hergeth SP, Aicher WK, Essl M, Schreiber TD,
Sasaki T, Klein G. Characterization and functional
analysis of osteoblast-derived fibulins in the
human hematopoietic stem cell niche. Exp
Hematol. 2008;36(8):1022-1034.
33. Lunter PC, van Kilsdonk JW, van Beek H, et al.
Activated leukocyte cell adhesion molecule
(ALCAM/CD166/MEMD), a novel actor in invasive
growth, controls matrix metalloproteinase activity.
Cancer Res. 2005;65(19):8801-8808.
34. Welte T, Zhang SS, Wang T, et al. STAT3
deletion during hematopoiesis causes Crohn’s
disease-like pathogenesis and lethality: a critical
role of STAT3 in innate immunity. Proc Natl Acad
Sci USA. 2003;100(4):1879-1884.
35. Mantel C, Messina-Graham S, Moh A, et al.
Mouse hematopoietic cell-targeted STAT3
deletion: stem/progenitor cell defects,
mitochondrial dysfunction, ROS overproduction,
and a rapid aging-like phenotype. Blood. 2012;
120(13):2589-2599.
36. Barata JT, Boussiotis VA, Yunes JA, et al.
IL-7-dependent human leukemia T-cell line as
a valuable tool for drug discovery in T-ALL. Blood.
2004;103(5):1891-1900.
37. Abramovich C, Pineault N, Ohta H, Humphries
RK. Hox genes: from leukemia to hematopoietic
stem cell expansion. Ann N Y Acad Sci. 2005;
1044(1):109-116.
38. Kiel MJ, Radice GL, Morrison SJ. Lack of
evidence that hematopoietic stem cells depend on
N-cadherin-mediated adhesion to osteoblasts for
their maintenance. Cell Stem Cell. 2007;1(2):
204-217.
BLOOD, 24 JULY 2014 x VOLUME 124, NUMBER 4 CD166 IDENTIFIES PRIMITIVE MURINE AND HUMAN HSC 529
For personal use only.on December 23, 2016. by guest  www.bloodjournal.orgFrom 
online April 16, 2014
 originally publisheddoi:10.1182/blood-2014-03-565721
2014 124: 519-529
 
 
Kamocka, Nadia Carlesso, Angelo A. Cardoso, Melissa A. Kacena and Edward F. Srour
Poteat, Hal E. Broxmeyer, Louis M. Pelus, Helmut Hanenberg, Amy Zollman, Malgorzata M. 
Brahmananda Reddy Chitteti, Michihiro Kobayashi, Yinghua Cheng, Huajia Zhang, Bradley A.
 
hematopoietic niche
CD166 regulates human and murine hematopoietic stem cells and the
 
http://www.bloodjournal.org/content/124/4/519.full.html
Updated information and services can be found at:
 (3381 articles)Hematopoiesis and Stem Cells    
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
For personal use only.on December 23, 2016. by guest  www.bloodjournal.orgFrom 
